XML 92 R37.htm IDEA: XBRL DOCUMENT v3.19.3
Investments in Nuclear Decommissioning Trusts and Other Special Use Funds (Tables)
9 Months Ended
Sep. 30, 2019
Investments, Debt and Equity Securities [Abstract]  
Fair value of APS's nuclear decommissioning trust fund assets
The following tables present the unrealized gains and losses based on the original cost of the investment and summarizes the fair value of APS's nuclear decommissioning trust and other special use fund assets at September 30, 2019 and December 31, 2018 (dollars in thousands):  
 
September 30, 2019
 
Fair Value
 
Total
Unrealized
Gains
 
Total
Unrealized
Losses
Investment Type:
Nuclear Decommissioning Trust
 
Other Special Use Funds
 
Total
 
 
Equity securities
$
485,467

 
$
1,982

 
$
487,449

 
$
297,032

 
$

Available for sale-fixed income securities
483,528

 
240,582

 
724,110

(a)
28,750

 
(476
)
Other
(1,322
)
 
1,418

 
96

(b)

 

Total
$
967,673

 
$
243,982

 
$
1,211,655

 
$
325,782

 
$
(476
)

(a)
As of September 30, 2019, the amortized cost basis of these available-for-sale investments is $696 million.
(b)
Represents net pending securities sales and purchases.

 
December 31, 2018
 
Fair Value
 
Total
Unrealized
Gains
 
Total
Unrealized
Losses
Investment Type:
Nuclear Decommissioning Trust
 
Other Special Use Funds
 
Total
 
 
Equity securities
$
402,008

 
$
45,130

 
$
447,138

 
$
222,147

 
$
(459
)
Available for sale-fixed income securities
446,978

 
190,378

 
637,356

(a)
8,634

 
(6,778
)
Other
2,148

 
593

 
2,741

(b)

 

Total
$
851,134

 
$
236,101

 
$
1,087,235

 
$
230,781

 
$
(7,237
)

(a)
As of December 31, 2018, the amortized cost basis of these available-for-sale investments is $635 million.
(b)
Represents net pending securities sales and purchases.
    
Realized gains and losses and proceeds from the sale of securities by the nuclear decommissioning trust funds
The following table sets forth APS's realized gains and losses relating to the sale and maturity of available-for-sale debt securities and equity securities, and the proceeds from the sale and maturity of these investment securities for the three and nine months ended September 30, 2019 and 2018 (dollars in thousands):
 
Three Months Ended September 30,
 
Nuclear Decommissioning Trust
 
Other Special Use Funds
 
Total
2019
 
 
 
 
 
Realized gains
$
4,732

 
$
4

 
$
4,736

Realized losses
(2,360
)
 

 
(2,360
)
Proceeds from the sale of securities (a)
155,386

 
56,255

 
211,641

2018
 
 
 
 
 
Realized gains
$
653

 
$

 
$
653

Realized losses
(1,965
)
 

 
(1,965
)
Proceeds from the sale of securities (a)
148,150

 
25,127

 
173,277


(a)
Proceeds are reinvested in the nuclear decommissioning trust and coal reclamation escrow account.

 
Nine Months Ended September 30,
 
Nuclear Decommissioning Trust
 
Other Special Use Funds
 
Total
2019
 
 
 
 
 
Realized gains
$
8,478

 
$
4

 
$
8,482

Realized losses
(5,465
)
 

 
(5,465
)
Proceeds from the sale of securities (a)
371,538

 
149,458

 
520,996

2018
 
 
 
 
 
Realized gains
$
2,951

 
$
1

 
$
2,952

Realized losses
(6,990
)
 

 
(6,990
)
Proceeds from the sale of securities (a)
401,396

 
41,644

 
443,040



(a)
Proceeds are reinvested in the nuclear decommissioning trust and coal reclamation escrow account.
Fair value of fixed income securities, summarized by contractual maturities
The fair value of APS's fixed income securities, summarized by contractual maturities, at September 30, 2019, is as follows (dollars in thousands):
 
Nuclear Decommissioning Trust (a)
 
Coal Reclamation Escrow Account
 
Active Union Medical Trust
 
Total
Less than one year
$
40,309

 
$
32,628

 
$
37,013

 
$
109,950

1 year – 5 years
133,488

 
25,928

 
140,895

 
300,311

5 years – 10 years
103,973

 
720

 

 
104,693

Greater than 10 years
205,758

 
3,398

 

 
209,156

Total
$
483,528

 
$
62,674

 
$
177,908

 
$
724,110


(a)
Includes certain fixed income investments that are not due at a single maturity date. These investments have been allocated within the table based on the final payment date of the instrument.